Grade My Investments
HomeFree Stock Grades › BIIB

Biogen Inc. (BIIB) Stock Grade

BIIB · Healthcare

B-
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$25.8B
P/E Ratio
20.0
Revenue Growth (YoY)
+1.4%
Net Margin
13.2%
Return on Equity
7.1%
Dividend Yield
None

About Biogen Inc.'s fundamentals

Biogen is a large-cap pharmaceutical company with a market capitalization of $25.8 billion, currently trading at a P/E ratio of 20.0. The company generated a net margin of 13.2%, reflecting solid profitability on its revenue base, though year-over-year revenue growth remains modest at 1.4%. Return on equity stands at 7.1%, indicating relatively modest returns on shareholder capital, and the company does not currently pay a dividend.

Track BIIB free — no credit card required. Live grade + monthly AI report →